Pulmonary Arterial Hypertension

Endothelin Receptor Antagonists (ERAs) to Hold Over 45% Revenue Share in Global Pulmonary Arterial Hypertension (PAH) Market: Fact.MR

Fact.MR, a market research and competitive intelligence provider, has conducted a comprehensive analysis on the pulmonary arterial hypertension (PAH) market, which is expected to rise at a CAGR of 5.4% …

Endothelin Receptor Antagonists (ERAs) to Hold Over 45% Revenue Share in Global Pulmonary Arterial Hypertension (PAH) Market: Fact.MR Read More